• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

    1.695 -0.455 (-21.16%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ProKidney Corp. - Class A Ordinary Shares

    < Previous 1 2 Next >
    ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the UBS Virtual Organ Restoration Day
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in the Jefferies Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Business Updates and First Quarter 2024 Financial Results
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in Jefferies Biotech on the Bay Summit
    From ProKidney
    Via GlobeNewswire
    ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
    Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney 
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Third Quarter Financial Results
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
    Total of 6 abstracts accepted for publication in Kidney Week 2023 program 
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
    From ProKidney
    Via GlobeNewswire
    ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
    From ProKidney
    Via GlobeNewswire
    ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
    From ProKidney
    Via GlobeNewswire
    ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
    From ProKidney
    Via GlobeNewswire
    ProKidney to Present at the BofA Securities Health Care Conference 2023
    From ProKidney
    Via GlobeNewswire
    ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
    From ProKidney
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.